Date: 2014-11-26
Type of information: Nomination
Compound: chief financial officer
Company: Bone Therapeutics (Belgium)
Therapeutic area: Bone diseases - Regenerative medicine
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On November 24, 2014, Bone Therapeutics, the regenerative therapy company addressing unmet medical needs in the fields of bone diseases and orthopaedics, announced the appointment of Dr Guy Heynen as Chief Clinical and Regulatory Officer. Dr Heynen will support Bone Therapeutics as it progresses its pipeline of regenerative bone disease and orthopaedic therapies through clinical development towards commercialisation.
Dr Heynen is a specialist in rheumatology and immunology, with extensive experience both in university medical practice and in the pharmaceutical industry. He has over 35 years’ experience in medical and regulatory affairs at local, regional and international levels and has a particular focus on management, team building and leadership. The majority of his career has been with Pfizer Inc., where he held a number of senior roles including Medical Director for Pfizer Switzerland, European Team Leader for the Alzheimer’s disease drug, Aricept, and Medical Team Leader for Pfizer’s anti-inflammatory drug franchise based in New York. Dr Heynen also serves on the Boards of Euroscreen SA, Progenosis SA and as an advisor for Promethera Biosciences, roles which highlight his expertise and strong network in cell therapy. Dr Heynen remains a Regional Medical Monitor for Pfizer GmbH.
Dr Heynen started his career at the Belgian National Foundation for Research and in research roles at University Hospital, Liege, Belgium where he received his degree in medicine and rheumatology.
Financial terms:
Latest news:
Is general: Yes
